Acumen Prescription drugs (NASDAQ:ABOS – Get Rating) experienced its selling price goal dropped by inventory analysts at Credit rating Suisse Group from $26.00 to $17.00 in a analysis notice issued on Tuesday, The Fly reports. Credit rating Suisse Group’s price concentrate on signifies a potential upside of 264.81% from the company’s recent selling price.
Numerous other exploration companies have also recently commented on ABOS. Zacks Expense Exploration lifted shares of Acumen Prescription drugs from a “keep” ranking to a “obtain” ranking and established a $6.75 rate target on the stock in a analysis be aware on Thursday, March 10th. Bank of The usa raised shares of Acumen Pharmaceuticals from a “neutral” ranking to a “invest in” rating and lessened their rate goal for the business from $16.00 to $14.00 in a investigation be aware on Friday, January 21st. Five analysts have rated the stock with a buy score, According to MarketBeat, the company has an typical score of “Purchase” and an regular target rate of $18.35.
NASDAQ ABOS opened at $4.66 on Tuesday. The organization has a 50 working day moving typical of $5.49 and a 200-day going normal of $9.01. Acumen Prescription drugs has a 1-yr reduced of $4.60 and a 1-yr superior of $26.98.
Hedge resources have not long ago modified their holdings of the business. Citigroup Inc. increased its stake in Acumen Pharmaceuticals by 255.7% in the 4th quarter. Citigroup Inc. now owns 3,891 shares of the company’s inventory valued at $26,000 soon after buying an more 2,797 shares during the past quarter. New York State Popular Retirement Fund obtained a new stake in Acumen Pharmaceuticals in the 4th quarter valued at $37,000. JPMorgan Chase & Co. enhanced its stake in Acumen Pharmaceuticals by 97.2% in the 4th quarter. JPMorgan Chase & Co. now owns 7,240 shares of the company’s inventory valued at $49,000 after shopping for an extra 3,568 shares through the last quarter. California State Instructors Retirement Program bought a new place in shares of Acumen Pharmaceuticals in the 3rd quarter valued at about $77,000. Lastly, American Worldwide Team Inc. acquired a new situation in shares of Acumen Pharmaceuticals in the 3rd quarter valued at about $78,000. Hedge money and other institutional traders very own 65.55% of the company’s inventory.
About Acumen Pharmaceuticals (Get Ranking)
Acumen Prescribed drugs, Inc, a clinical-phase biopharmaceutical company, engages in the development of therapeutics for the treatment method of Alzheimer’s and other neurodegenerative illnesses. The company focuses on advancing a qualified immunotherapy drug candidate ACU193, which is in Stage I clinical-phase to target soluble amyloid-beta oligomers.
This instantaneous information notify was produced by narrative science technological innovation and money information from MarketBeat in get to supply audience with the speediest and most exact reporting. This tale was reviewed by MarketBeat’s editorial workforce prior to publication. Be sure to mail any queries or responses about this tale to [email protected]
Really should you invest $1,000 in Acumen Prescribed drugs appropriate now?
Just before you look at Acumen Prescribed drugs, you can want to hear this.
MarketBeat keeps monitor of Wall Street’s major-rated and finest carrying out research analysts and the shares they recommend to their consumers on a day by day basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their consumers to invest in now prior to the broader industry catches on… and Acumen Prescription drugs wasn’t on the checklist.
Although Acumen Prescription drugs at the moment has a “Invest in” ranking between analysts, leading-rated analysts consider these 5 stocks are much better buys.
Perspective The 5 Stocks Below